Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 18, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them, rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transaction details:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction 1: Sale of 20,000 shares at a price of £13.1044 per share.
- Transaction 2: Sale of 32,974 shares at a price of £13.0911 per share.
- Total Volume Reported: 52,974 Ordinary shares.
- Exchange: London Stock Exchange, Main Market (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely discloses the reduction in shareholdings of specific individuals on the reporting date.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is strictly limited to regulatory disclosure of the transactions listed above.
Investor Verification Checklist
- Verify the identity of the sellers: Dr. P J T Vallance (President, R&D) and Mrs. S Vallance (Person Closely Associated).
- Confirm the total number of shares sold (52,974) and the weighted average price against market data for December 18, 2017.
- Check subsequent filings to determine the remaining shareholdings of these individuals post-transaction.
- Note that this filing contains no operational or financial performance data; refer to the latest Form 20-F or quarterly reports for those metrics.